AKIR001 is a targeted antibody–radionuclide conjugate being evaluated in a Phase I trial for patients with CD44v6-positive, unresectable or metastatic solid tumours. The study is being conducted at Karolinska University Hospital in Stockholm and includes lung, head and neck, thyroid and gynaecological cancers.

Lutetium-177 is the active radioactive payload in AKIR001. The isotope is attached to Akiram’s proprietary antibody targeting CD44v6, a cancer marker associated with several aggressive tumour types. The approach is designed to deliver radiation selectively to tumour cells while limiting exposure to healthy tissue.

“We are pleased to partner with ITM, a leading global producer and supplier of n.c.a. Lu-177, as we continue advancing AKIR001 through clinical development,” said Marika Nestor, CEO of Akiram Therapeutics.

The financial terms of the agreement were not disclosed. ITM will supply lutetium-177 for Akiram’s ongoing clinical trial and related research activities.